Investors Research Corp Cuts Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Investors Research Corp lowered its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,194 shares of the company’s stock after selling 2,600 shares during the quarter. Investors Research Corp’s holdings in Takeda Pharmaceutical were worth $572,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of TAK. Versant Capital Management Inc purchased a new position in Takeda Pharmaceutical during the 4th quarter worth $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth $40,000. BNP Paribas Financial Markets grew its stake in shares of Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the period. Smithfield Trust Co grew its stake in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth $52,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $15.04 on Tuesday. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.22. The stock has a market cap of $47.84 billion, a PE ratio of 37.59, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The firm’s fifty day simple moving average is $13.62 and its 200-day simple moving average is $13.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.